Next Generation Extended Wear Sensors in Type 1 and Type 2 Diabetes
Official title: Evaluation of MiniMed Next Generation Extended Wear Sensors and Algorithm in Patients With Type 1 and Type 2 Diabetes
Run by Medtronic MiniMed, Inc. · NCT07864168 · Data updated 2026-11-12
This study tests a new extended wear sensor and algorithm in people with type 1 or type 2 diabetes to see how well it works across adults and children.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 2 Years to 80 Years |
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | Medtronic MiniMed, Inc. Industry-sponsored |
| Drugs / interventions | radiation |
| Locations | 18 sites (Chula Vista, California and 17 other locations) |
| Status | Recruiting |
| Started | October 5, 2026 |
| Main results expected | December 2027 |
| Study ends | December 2027 |
| Registry record updated | October 20, 2026 |
| Trial ID | NCT07864168 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children and adults aged 2–80 years with a clinical diagnosis of type 1 or type 2 diabetes for at least six months (or since aged 2–10 years for younger participants) who are willing to wear the device continuously and provide consent/assent.
✕Probably not a fit
Patients whose diabetes management does not rely on continuous sensor wear or who cannot tolerate extended sensor use may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multi-center, prospective, single-arm study evaluating the performance of MiniMed's next generation extended wear sensors and accompanying algorithm in both adult and pediatric participants with type 1 or type 2 diabetes. It enrolls participants aged 2 to 80 years and follows them for up to 46 days per subject, with a total study duration of about 24 months to complete all centers. There are no concurrent control subjects; all participants receive the investigational sensor. The trial requires ongoing device wear, fingerstick glucose checks as needed, and informed consent from participants or guardians. Study sites include ProSciento, Stanford University, and Rady Children’s Hospital San Diego, with Medtronic MiniMed, Inc. as lead sponsor.
Why it matters
Potential benefit: If successful, participants may benefit from improved glucose sensing through the extended wear sensor, potentially aiding diabetes management.
How similar studies have gone: Previous studies of continuous glucose sensing technologies have shown feasibility and accuracy in diabetes care, though this specific extended wear sensor/algorithm is being evaluated in a single-arm design.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
1. Age 2-80 years at time of screening.
2. Has a clinical diagnosis of diabetes as stipulated according to the following age group:
1. Age 2-10 years: Has a clinical diagnosis of T1D or T2D as determined via medical record/ source documentation by an individual qualified to make a medical diagnosis.
2. Age 11-80 years: Has a clinical diagnosis of T1D or T2D for 6 months or more, as determined via medical record or source documentation by an individual qualified to make a medical diagnosis.
3. Subject or parent(s)/ guardian(s)/ caregiver(s) is/are literate and able to read the language offered in the study materials.
4. Is willing to provide informed consent/assent for participation.
5. If participating in BGA FST, has adequate venous access as assessed by investigator or appropriate staff.
6. Is willing to perform fingerstick blood glucose measurements as needed.
7. Is willing to wear the study devices continuously throughout the study.
8. Subject or parent(s)/guardian(s)/caregiver(s) is/are willing to complete the requirements for diary data entry, as applicable.
9. If participating in glycemic challenges, has met the following conditions:
1. Been using insulin for at least 3 months
2. A relatively stable insulin-to-carbohydrate ratio(s) and insulin sensitivity factor(s) for at least one month per investigator assessment Subjects who do not meet the above conditions can be included in the study, however, will participate in the FST under observation only (no glycemic challenges).
Exclusion Criteria:
1. Unable to consent due to a mental or intellectual disability.
2. Has a history of 1 or more episodes of severe hypoglycemia during the 6 months prior to screening visit.
3. Has had a hypoglycemic seizure within the past 6 months prior to screening visit.
4. Has had hypoglycemia resulting in loss of consciousness within the past 6 months prior to enrollment.
5. Has a history of 1 or more episodes of DKA in the last 6 months prior to screening visit.
6. T2D: Has had hyperglycemic hyperosmolar syndrome (HHS) in the last 6 months prior to screening visit.
7. Has a history of a seizure disorder.
8. Has a central nervous system or cardiac disorder resulting in syncope.
9. Will not tolerate tape adhesive in the area of sensor placement as assessed by a qualified individual.
10. Has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).
11. Currently pregnant or planning to become pregnant during the time period of study participation
1. A negative pregnancy test will be required for all females of child-bearing potential at time of screening
2. For sexually active females of child-bearing potential the investigator will use discretion to determine if the form of contraception that is being used is reliable
12. Has diagnosis of adrenal insufficiency.
13. Is using hydroxyurea at time of screening or plans to use it during the study.
14. Is participating in another pharmaceutical or device trial within 2 weeks of enrollment or anticipates participation in another trial during the course of the study. (Please note participation in an observational study is acceptable.)
15. Has a planned procedure involving the use of a Magnetic Resonance Imaging (MRI), diathermy devices, or other devices that generate strong magnetic fields (e.g., x-ray, CT scan, or other types of radiation) during the study wear period.
16. Has elective surgery planned that requires general anesthesia during the course of the study.
17. T2D: Is using insulin secretagogue.
18. Is, at the discretion of the investigator, abusing drugs or alcohol
19. Age 7-80 years: has a hematocrit (Hct) more than 10% below the lower limit of normal reference range (please note that prior blood draw from routine care may be used as long as the prior blood draw was done within 3 months prior to screening and report of lab placed with subject source documents).
20. Has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances.
21. Has had any of the following cardiovascular events more than 1 year prior to screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances. However, subject may participate at the discretion of the investigator and with clearance from the cardiologist.
22. Has any other disease or condition that may preclude the patient from participating in the study, per investigator judgment.
23. Is a member of the research staff involved with the study.
24. Is a sponsor employee or their immediate family member (excluding adult children and/or adult siblings).
Where it's running
-
ProSciento
Chula Vista, California, United States Recruiting -
Sansum Diabetes Research Institute
Santa Barbara, California, United States Recruiting -
Diablo Clinical Research, Inc.
Walnut Creek, California, United States Recruiting -
Barbara Davis Center for Diabetes
Aurora, Colorado, United States Recruiting -
Barbara Davis Center for Diabetes
Aurora, Colorado, United States Recruiting -
Atlanta Diabetes Associates
Atlanta, Georgia, United States Recruiting
Show 12 more locations
-
Rocky Mountain Clinical Research
Idaho Falls, Idaho, United States Recruiting -
Texas Diabetes and Endocrinology
Austin, Texas, United States Recruiting -
Diabetes and Glandular Disease Clinic
San Antonio, Texas, United States Recruiting -
University of Virginia Health System
Charlottesville, Virginia, United States Recruiting -
Rainier Clinical Research Center
Renton, Washington, United States Recruiting -
Stanford University
Palo Alto, California, United States Not yet recruiting -
Rady Children's Hospital - San Diego
San Diego, California, United States Not yet recruiting -
University of California San Francisco UCSF The Madison Clinic for Pediatric Diabetes
San Francisco, California, United States Not yet recruiting -
Yale University School of Medicine
New Haven, Connecticut, United States Not yet recruiting -
University of Florida
Gainesville, Florida, United States Not yet recruiting -
University of South Florida (USF) Diabetes and Endocrinology Center
Tampa, Florida, United States Not yet recruiting -
Seattle Children's
Seattle, Washington, United States Not yet recruiting
Study contacts
- Study coordinator: Robin Mottackel
- Email: robin.e.mottackel@medtronic.com
- Phone: 818-576-4886
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
NOURISH: a community partnership to improve nutrition and glycemic control in pregnant women with pregestational diabetes
Aiming to test a healthcare-community program that delivers healthy food weekly and provides nutrition education to pregnant women with type 1 or type 2 diabetes who have food insecurity, to improve blood sugar and pregnancy outcomes.
-
Permissive versus strict blood sugar control during labor for pregnant people with type 1 diabetes
This trial will test whether allowing slightly higher blood sugars (70–140 mg/dL) during labor is as safe for newborns as keeping tighter control (70–110 mg/dL) for pregnant people with type 1 diabetes using hybrid closed‑loop insulin systems.
-
Blood sugar control and a GLP-1 medicine's effect on islet GLP-1 in people with type 1 or type 2 diabetes
We will test whether tighter blood sugar control and a GLP-1 drug (liraglutide) change islet GLP-1 in people with type 1 or type 2 diabetes who use insulin.
-
Evaluation of a dosing guidance system for diabetes management
This study is testing a new system that helps people with Type 1 and Type 2 diabetes manage their insulin doses better to see if it improves their blood sugar control.
-
Investigating mortality and cardiovascular diseases in adults with type 1 diabetes
This study looks at how type 1 diabetes affects the risk of dying and heart problems in adults compared to those with type 2 diabetes and people without diabetes.
-
Nationwide registry of pregnancies in women with diabetes
This study is trying to gather information about pregnancies in women with diabetes to see how their health and their babies' health are affected, and to find better ways to support them during and after pregnancy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.